Polish diabetes group "devastated" over reimbursement list
The Polish Association of Diabetic Patients (PSD) has said it is "devastated" at the absence from the new reimbursement lists, sent out for consultation on December 31, 2008, of long-acting insulin analogs, even though assurances had been given by the Health Ministry that these products would be included.
PSD president Andrzej Bauman told the local newspaper Puls Medycyny that, by backtracking on her pledge, Ewa Kopacz missed a chance to become the first Health Minister to make this historic commitment of vital importance to the effective diabetes treatment in Poland. This view was echoed by leading diabetologists, notes the PMR consulting group.
Shortly before Christmas, the PSD announced that the last formal hurdle to making long-acting analogs subject to state financing was removed after AOTM, the health technologies' assessment agency, issued a positive recommendation for such a move.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze